American Journal of BioMedicine  Volume 2, Issue 8, pages 887-898, August 2014


1. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barre syndrome. Clin Microbiol Rev 1998;11: 555–567.  [PubMed]

2. de Jager AE, Sluiter HJ. Clinical signs in severe Guillain-Barre syndrome: analysis of 63 patients. J Neurol Sci 1991; 104: 143–150. [PubMed]

3. Ropper AH. The Guillain-Barre syndrome. N Engl J Med  1992; 326: 1130–1136. [PubMed]

4. Hughes RAC, Cornblath DR. Guillain-Barré syndrome. Lancet 2005; 366: 1653–1666. [PubMed]

5. Kang JH, Sheu JJ, Lin HC. Increased risk of Guillain-Barré syndrome following recent herpes zoster: A population-based study across Taiwan. Clin Infect Dis 2010; 51: 525–530. [PubMed]

6. Wim Ang C, Jacobs BC, Laman JD. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004; 25: 61–66. [PubMed]

7. Kusunoki S, Kaida K. Antibodies against ganglioside complexes in Guillain-Barré syndromé and related disorders. J Neurochem 2011; 116: 828–832. [PubMed]

8. Boldron J, Caltabiano S, Debono SD, Thompson R, Scammells M, Westover R, Wu Y, Frugier P. Adhesion molecule expression trigger immune-mediated pathology in lupus-nephritis. American Journal of BioMedicine  2013;1(2): 49–57. [Abstract/Full-Text]

9. Gabriel CM, Gregson NA, Hughes RAC. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol 2000;104: 139–146. [PubMed]

10. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004; 30: 131–156. [PubMed]

11. Marchiori PE, Dos Reis M, Quevedo ME, Callegaro D, Hirata MT, et al. Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. Arq Neuropsiquiatr 1990; 48: 465–468. [PubMed]

12. Nishino S, Kanbayashi T, Fujiki N, Uchino M, Ripley B, et al. CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies. Neurology 2003; 61: 823–825. [PubMed]

13. Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, et al. Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clin Chim Acta 2009; 405: 143–147. [PubMed]

14. Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Naldi P, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010; 51: 138–143. [PubMed]

15. Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci 2008; 15: 1031–1035. [PubMed]

16. Sheu JY, Kulhanek DJ, Eckenstein FP. Differential patterns of ERK and STAT3 phosphorylation after sciatic nerve transection in the rat. Exp Neurol 2000; 166: 392–402. [PubMed]

17. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: SupplS21–24. [PubMed]

18. Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009;40(11):3443-3448. [Abstract/FREE Full Text]

19. Ormerod IE, Cockerell OC. Guillain-Barrésyndrome after herpes zoster infection: a report of 2 cases. Eur Neurol 1993; 33(2):156-158. [PubMed]

20. Pavone P, Maccarrone F, Sorge A, Piccolo G, Greco F, Caruso P, Sorge G. Guillain-Barré syndrome after varicella zoster virus infections. A case report. Minerva Pediatr. 2002; 54(3): 259-62. [PubMed]

21. Yoshikawa T, Suzuki K, Suga S, Miyata E, Yamamoto H, Hosokawa T, Kumagai T, Asano Y. Immune response to gangliosides in a case of Guillain-Barré syndrome after varicella. Arch Dis Child 2000 ;83(2):172-3. [PubMed]

22. Sugiyama N, Hamano S, Koga M. High-dose intravenous immunoglobulin therapy in a child case of Bickerstaff's brainstem encephalitis. No To Hattatsu 2003 ;35(4): 327-30. [PubMed]

23. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci 2004 ;219(1-2):139-45. [PubMed]

24. Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, Kuwabara S. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003 ;126(Pt 10): 2279-90. [PubMed]

25. Nyati KK, Prasad KN, Verma A, Paliwal VK. Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barré syndrome. J Neurosci Res 2010; 88: 3540–3546. [PubMed]

26. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27: SupplS21–24. [PubMed]

27. Grotenhuis N, Vd Toom HF, Kops N, Bayon Y, Deerenberg EB, Mulder IM, van Osch GJ, Lange JF, Bastiaansen-Jenniskens YM. In vitro model to study the biomaterial-dependent reaction of macrophages in an inflammatory environment. Br J Surg 2014 ;101(8): 983-92. [PubMed]

28. Greenhalgh AD, David S. Differences in the phagocytic response of microglia and peripheral macrophages after spinal cord injury and its effects on cell death. J Neurosci 2014; 34(18): 6316-22. [PubMed]

29. Wu X, Wu W2, Wang Z, Shen D, Pan W, Wang Y, Wu L, Wu X, Feng J, Liu K, Zhu J, Zhang HL. More Severe Manifestations and Poorer Short-Term Prognosis of Ganglioside-Associated Guillain-Barré Syndrome in Northeast China. PLoS One. 2014 ;9(8):e104074. [PubMed]

30. Komagamine T, Yuki N. Ganglioside mimicry as a cause of Guillain-Barré syndrome. CNS Neurol Disord Drug Targets 2006;5(4):391-400. [PubMed]

31. Inés González-Suárez, Irene Sanz-Gallego, Francisco Rodríguez de Rivera, Javier Arp. Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurology 2013; 13:95. [Abstract/Full-text]

Print Friendly, PDF & Email